Targeted Nucleotide Editing Technologies for Microbial Metabolic Engineering

被引:39
作者
Arazoe, Takayuki [1 ]
Kondo, Akihiko [2 ,3 ]
Nishida, Keiji [2 ]
机构
[1] Tokyo Univ Sci, Dept Appl Biol Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan
[2] Technol & Innovat Kobe Univ, Grad Sch Sci, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan
[3] Kobe Univ, Grad Sch Engn, Dept Chem Sci & Engn, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan
关键词
base editing; CRISPR; Cas9; genome editing; metabolic engineering; microbial engineering; BACTERIAL GENE-EXPRESSION; ESCHERICHIA-COLI GENOME; STAPHYLOCOCCUS-AUREUS; CLOSTRIDIUM-BEIJERINCKII; GUIDE-RNA; E; COLI; CRISPR; BASE; DNA; RECOMBINATION;
D O I
10.1002/biot.201700596
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Since the emergence of programmable RNA-guided nucleases based on clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) systems, genome editing technologies have become a simplified and versatile tool for genome editing in various organisms and cell types. Although genome editing enables efficient genome manipulations, such as gene disruptions, gene knockins, and chromosomal translocations via DNA double-strand break (DSB) repair in eukaryotes, DSBs induced by the CRISPR/Cas system are lethal or severely toxic to many microorganisms. Therefore, in many prokaryotes, including industrially useful microbes, the CRISPR/Cas system is often used as a negative selection component in combination with recombineering or other related strategies. Novel and revolutionary technologies have been recently developed to re-write targeted nucleotides (C:G to T:A and A:T to G:C) without DSBs and donor DNA templates. These technologies rely on the recruitment of deaminases at specific target loci using the nuclease-deficient CRISPR/Cas system. Here, the authors review and compare CRISPR-based genome editing, current base editing platforms and their spectra. The authors discuss how these technologies can be applied in various aspects of microbial metabolic engineering to overcome barriers to cellular regulation in prokaryotes.
引用
收藏
页数:12
相关论文
共 129 条
  • [1] Mechanisms of Programmed DNA Lesions and Genomic Instability in the Immune System
    Alt, Frederick W.
    Zhang, Yu
    Meng, Fei-Long
    Guo, Chunguang
    Schwer, Bjoern
    [J]. CELL, 2013, 152 (03) : 417 - 429
  • [2] Editing of the Bacillus subtilis Genome by the CRISPR-Cas9 System
    Altenbuchner, Josef
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2016, 82 (17) : 5421 - 5427
  • [3] Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240
  • [4] CRISPR/Cas9-Based Counterselection Boosts Recombineering Efficiency in Pseudomonas putida
    Aparicio, Tomas
    de Lorenzo, Victor
    Martinez-Garcia, Esteban
    [J]. BIOTECHNOLOGY JOURNAL, 2018, 13 (05)
  • [5] M-path: a compass for navigating potential metabolic pathways
    Araki, Michihiro
    Cox, Robert Sidney, III
    Makiguchi, Hiroki
    Ogawa, Teppei
    Taniguchi, Takeshi
    Miyaoku, Kohei
    Nakatsui, Masahiko
    Hara, Kiyotaka Y.
    Kondo, Akihiko
    [J]. BIOINFORMATICS, 2015, 31 (06) : 905 - 911
  • [6] Deaminase-mediated multiplex genome editing in Escherichia coli
    Banno, Satomi
    Nishida, Keiji
    Arazoe, Takayuki
    Mitsunobu, Hitoshi
    Kondo, Akihiko
    [J]. NATURE MICROBIOLOGY, 2018, 3 (04): : 423 - 429
  • [7] Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system
    Bikard, David
    Jiang, Wenyan
    Samai, Poulami
    Hochschild, Ann
    Zhang, Feng
    Marraffini, Luciano A.
    [J]. NUCLEIC ACIDS RESEARCH, 2013, 41 (15) : 7429 - 7437
  • [8] Making ends meet: Repairing breaks in bacterial DNA by non-homologous end-joining
    Bowater, Richard
    Doherty, Aidan J.
    [J]. PLOS GENETICS, 2006, 2 (02): : 93 - 99
  • [9] CRISPRi-sRNA: Transcriptional-Translational Regulation of Extracellular Electron Transfer in Shewanella oneidensis
    Cao, Yingxiu
    Li, Xiaofei
    Li, Feng
    Song, Hao
    [J]. ACS SYNTHETIC BIOLOGY, 2017, 6 (09): : 1679 - 1690
  • [10] In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing
    Chadwick, Alexandra C.
    Wang, Xiao
    Musunuru, Kiran
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37 (09) : 1741 - +